Search - tctmd.com

Displaying 1 - 20 of 244

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2019

Shelley Wood

December 31, 2019

News Daily News

FDA Approves Two Generic Versions of Apixaban

Todd Neale

December 23, 2019

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Shelley Wood

December 23, 2019

News Features

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

Michael O'Riordan

December 18, 2019

News Daily News

FDA: Class I Recall for Cook Medical’s CrossCath Support Catheters

L.A. McKeown

December 17, 2019

News Features

Year in Review: Payment Fights, Wearables, Burnout Defined Cardiology Practice in 2019

Caitlin E. Cox

December 17, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Features

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

L.A. McKeown

December 12, 2019

News Daily News

FDA Advisors Decline to Recommend Vernakalant Approval

Shelley Wood

December 11, 2019

News Daily News

FDA Is Surveilling Heparin but Believes Defective Quality Unlikely

Yael L. Maxwell

December 06, 2019

News Daily News

Long-term Watchman Data Reassure: CAP and CAP2 Registries

Michael O'Riordan

December 02, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2019

Shelley Wood

November 29, 2019

News Features

Subtherapeutic Heparin: As Stories Multiply, Concerns Mount

Yael L. Maxwell

November 27, 2019

Two Small Series Support Role for Cerebral Protection in TAVR

Michael O'Riordan

November 18, 2019

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

News Conference News AHA 2019

More Adverse Events, Higher Costs With Impella: New Observational Studies

Caitlin E. Cox

November 17, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Conference News VIVA 2019

Future Pulmonary Embolism Interventions: Wild West or Working Together?

L.A. McKeown

November 14, 2019

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

Advertisement

TCTMD’s Top 10 Most Popular Stories for December 2019

FDA Approves Two Generic Versions of Apixaban

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too

FDA: Class I Recall for Cook Medical’s CrossCath Support Catheters

Year in Review: Payment Fights, Wearables, Burnout Defined Cardiology Practice in 2019

FDA Approves Icosapent Ethyl for Reducing CVD Events

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

FDA Advisors Decline to Recommend Vernakalant Approval

FDA Is Surveilling Heparin but Believes Defective Quality Unlikely

Long-term Watchman Data Reassure: CAP and CAP2 Registries

TCTMD’s Top 10 Most Popular Stories for November 2019

Subtherapeutic Heparin: As Stories Multiply, Concerns Mount

Two Small Series Support Role for Cerebral Protection in TAVR

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

More Adverse Events, Higher Costs With Impella: New Observational Studies

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Future Pulmonary Embolism Interventions: Wild West or Working Together?

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content